FDA records linked by MedtechLedger identify GE Healthcare Finland Oy as the applicant behind 510(k) K260656, a Traditional premarket notification with a Summary, with the Cardiovascular advisory committee designation under product code MHX. The filing lists Carescape ONE, Carescape Dock F0, TruSignal ECG MM, TruSignal PRES MM, TruSignal TEMP MM, TruSignal SpO2 MM 1.8M and TruSignal SpO2 MM 3.0M. The applicant contact is Anssi Ruokonen, Program Manager, Regulatory Affairs, Monitoring Solutions, at a Helsinki address in the filing. [1][2][3]

The K260656 clearance and its scope

The K260656 clearance letter gives Dated as February 27, 2026 and Received as July 27, 2026. FDA recorded its decision on September 1, 2026 with decision code SESE, described as Substantially Equivalent, and a third-party review flag of N. The FDA record places it under regulation number 870.1025, arrhythmia detector and alarm including ST-segment measurement and alarm, Class II, product code MHX, with the openFDA device name Monitor, Physiological, Patient (With Arrhythmia Detection Or Alarms). The clearance letter lists additional product codes alongside MHX. [1][3]

The applicant's own conclusion in the filing states that it considers the listed Carescape ONE, Carescape Dock F0 and TruSignal micro-modules substantially equivalent to the predicate device. That is the applicant's stated position in the document, not an independent clinical finding. [3]

Documented hardware and modules

GE HealthCare's Carescape ONE brochure describes Carescape ONE as a FlexAcuity monitoring system with a monitor and micro-modules that flex across care areas and patient acuities without additional hardware or software configurations, and describes a standardized platform with one device and one software system for fleet management. The brochure carries software version v4, build v4.0. The global product page shows Carescape ONE with micro-module ports and CARESCAPE micro-modules. [4][9]

The TruSignal SpO2 page states that the accessories comply with IEC60601-1:2005, IEC 80601-2-61 and ISO9919:2009, as well as other standards. The Carescape ONE brochure states that compatible sensors are type BF defibrillation-proof applied parts per IEC 60601-1 Clause 8.3 and ISO 80601-2-61 Clause 201.8.3.101. These are manufacturer statements about standards compliance, not FDA findings in the cited filing. [4][7]

Published usability work

GE HealthCare's Carescape pages cite a 2025 evaluation usability study performed at GE HealthCare offices in Milwaukee, Wisconsin and Helsinki, Finland, in which eleven nurses were surveyed through a structured questionnaire, with reference to a marketing survey test procedure document. The pages present this as a usability evaluation; no clinical performance result is stated in the cited text. [5][6]

What the record does not establish

The collection retrieved for this profile contains one linked record, a 510(k) with a single SESE decision, and the record sample contains that same single entry; these counts describe the retrieved filings as of the snapshot date and are not measures of total portfolio, sales or safety performance. No recall records appear in the retrieved sample. The filing address in Helsinki is an FDA correspondence address and does not establish a headquarters location. Corporate ownership, customer relationships and commercial availability are not documented in the cited sources. [1][2][8]